These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 31932841)

  • 1. Dnmt3a loss and Idh2 neomorphic mutations mutually potentiate malignant hematopoiesis.
    Zhang X; Wang X; Wang XQD; Su J; Putluri N; Zhou T; Qu Y; Jeong M; Guzman A; Rosas C; Huang Y; Sreekumar A; Li W; Goodell MA
    Blood; 2020 Mar; 135(11):845-856. PubMed ID: 31932841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia.
    Chan SM; Majeti R
    Int J Hematol; 2013 Dec; 98(6):648-57. PubMed ID: 23949914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers.
    Glass JL; Hassane D; Wouters BJ; Kunimoto H; Avellino R; Garrett-Bakelman FE; Guryanova OA; Bowman R; Redlich S; Intlekofer AM; Meydan C; Qin T; Fall M; Alonso A; Guzman ML; Valk PJM; Thompson CB; Levine R; Elemento O; Delwel R; Melnick A; Figueroa ME
    Cancer Discov; 2017 Aug; 7(8):868-883. PubMed ID: 28408400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Model System for Studying the DNMT3A Hotspot Mutation (DNMT3A
    Lu R; Wang J; Ren Z; Yin J; Wang Y; Cai L; Wang GG
    Cancer Res; 2019 Jul; 79(14):3583-3594. PubMed ID: 31164355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leukemic mutations in the methylation-associated genes DNMT3A and IDH2 are rare events in pediatric AML: a report from the Children's Oncology Group.
    Ho PA; Kutny MA; Alonzo TA; Gerbing RB; Joaquin J; Raimondi SC; Gamis AS; Meshinchi S
    Pediatr Blood Cancer; 2011 Aug; 57(2):204-9. PubMed ID: 21504050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequentially inducible mouse models reveal that Npm1 mutation causes malignant transformation of Dnmt3a-mutant clonal hematopoiesis.
    Loberg MA; Bell RK; Goodwin LO; Eudy E; Miles LA; SanMiguel JM; Young K; Bergstrom DE; Levine RL; Schneider RK; Trowbridge JJ
    Leukemia; 2019 Jul; 33(7):1635-1649. PubMed ID: 30692594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA methylation and hydroxymethylation patterns in acute myeloid leukemia patients with mutations in DNMT3A and IDH1/2 and their combinations.
    Šestáková Š; Krejčík Z; Folta A; Cerovská E; Šálek C; Merkerová MD; Pecherková P; Ráčil Z; Mayer J; Cetkovský P; Remešová H
    Cancer Biomark; 2019; 25(1):43-51. PubMed ID: 30988238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of high-resolution melting analysis with direct sequencing for the detection of recurrent mutations in DNA methyltransferase 3A and isocitrate dehydrogenase 1 and 2 genes in acute myeloid leukemia patients.
    Gorniak P; Ejduk A; Borg K; Makuch-Lasica H; Nowak G; Lech-Maranda E; Prochorec-Sobieszek M; Warzocha K; Juszczynski P
    Eur J Haematol; 2016 Feb; 96(2):181-7. PubMed ID: 25891904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative examination of various PCR-based methods for DNMT3A and IDH1/2 mutations identification in acute myeloid leukemia.
    Berenstein R; Blau IW; Kar A; Cay R; Sindram A; Seide C; Blau O
    J Exp Clin Cancer Res; 2014 May; 33(1):44. PubMed ID: 24887327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic modifiers in normal and malignant hematopoiesis.
    Haladyna JN; Yamauchi T; Neff T; Bernt KM
    Epigenomics; 2015; 7(2):301-20. PubMed ID: 25942537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enforced differentiation of Dnmt3a-null bone marrow leads to failure with c-Kit mutations driving leukemic transformation.
    Celik H; Mallaney C; Kothari A; Ostrander EL; Eultgen E; Martens A; Miller CA; Hundal J; Klco JM; Challen GA
    Blood; 2015 Jan; 125(4):619-28. PubMed ID: 25416276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dnmt3a loss predisposes murine hematopoietic stem cells to malignant transformation.
    Mayle A; Yang L; Rodriguez B; Zhou T; Chang E; Curry CV; Challen GA; Li W; Wheeler D; Rebel VI; Goodell MA
    Blood; 2015 Jan; 125(4):629-38. PubMed ID: 25416277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia.
    Rau RE; Rodriguez BA; Luo M; Jeong M; Rosen A; Rogers JH; Campbell CT; Daigle SR; Deng L; Song Y; Sweet S; Chevassut T; Andreeff M; Kornblau SM; Li W; Goodell MA
    Blood; 2016 Aug; 128(7):971-81. PubMed ID: 27335278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents.
    DiNardo CD; Patel KP; Garcia-Manero G; Luthra R; Pierce S; Borthakur G; Jabbour E; Kadia T; Pemmaraju N; Konopleva M; Faderl S; Cortes J; Kantarjian HM; Ravandi F
    Leuk Lymphoma; 2014 Aug; 55(8):1925-9. PubMed ID: 24138309
    [No Abstract]   [Full Text] [Related]  

  • 15. Mutation and expression analysis of the IDH1, IDH2, DNMT3A, and MYD88 genes in colorectal cancer.
    Li WL; Xiao MS; Zhang DF; Yu D; Yang RX; Li XY; Yao YG
    Gene; 2014 Aug; 546(2):263-70. PubMed ID: 24887488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cooperating gene mutations in childhood acute myeloid leukemia with special reference on mutations of ASXL1, TET2, IDH1, IDH2, and DNMT3A.
    Liang DC; Liu HC; Yang CP; Jaing TH; Hung IJ; Yeh TC; Chen SH; Hou JY; Huang YJ; Shih YS; Huang YH; Lin TH; Shih LY
    Blood; 2013 Apr; 121(15):2988-95. PubMed ID: 23365461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association.
    Debarri H; Lebon D; Roumier C; Cheok M; Marceau-Renaut A; Nibourel O; Geffroy S; Helevaut N; Rousselot P; Gruson B; Gardin C; Chretien ML; Sebda S; Figeac M; Berthon C; Quesnel B; Boissel N; Castaigne S; Dombret H; Renneville A; Preudhomme C
    Oncotarget; 2015 Dec; 6(39):42345-53. PubMed ID: 26486081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNMT3A in Leukemia.
    Brunetti L; Gundry MC; Goodell MA
    Cold Spring Harb Perspect Med; 2017 Feb; 7(2):. PubMed ID: 28003281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies.
    Im AP; Sehgal AR; Carroll MP; Smith BD; Tefferi A; Johnson DE; Boyiadzis M
    Leukemia; 2014 Sep; 28(9):1774-83. PubMed ID: 24699305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue-Biased Expansion of DNMT3A-Mutant Clones in a Mosaic Individual Is Associated with Conserved Epigenetic Erosion.
    Tovy A; Reyes JM; Gundry MC; Brunetti L; Lee-Six H; Petljak M; Park HJ; Guzman AG; Rosas C; Jeffries AR; Baple E; Mill J; Crosby AH; Sency V; Xin B; Machado HE; Castillo D; Weitzel JN; Li W; Stratton MR; Campbell PJ; Wang H; Sanders MA; Goodell MA
    Cell Stem Cell; 2020 Aug; 27(2):326-335.e4. PubMed ID: 32673568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.